Carasent Future Growth

Future criteria checks 4/6

Carasent is forecast to grow earnings and revenue by 81.4% and 18.6% per annum respectively. EPS is expected to grow by 81.4% per annum. Return on equity is forecast to be 4.2% in 3 years.

Key information

81.4%

Earnings growth rate

81.4%

EPS growth rate

Healthcare Services earnings growth	30.0%
Revenue growth rate	18.6%
Future return on equity	4.2%
Analyst coverage	Low
Last updated	15 Nov 2024

Recent future growth updates

Recent updates

Carasent ASA's (OB:CARA) Intrinsic Value Is Potentially 73% Above Its Share Price

May 11

Is Carasent ASA (OB:CARA) Potentially Undervalued?

Mar 18

Is Now The Time To Look At Buying Carasent ASA (OB:CARA)?

Nov 22

Carasent's (OB:CARA) Solid Profits Have Weak Fundamentals

May 06

Returns Are Gaining Momentum At Carasent (OB:CARA)

Apr 29

Carasent ASA Beat Analyst Profit Forecasts, And Analysts Have New Estimates

Feb 13

There Are Reasons To Feel Uneasy About Carasent's (OB:CARA) Returns On Capital

Nov 24

Calculating The Intrinsic Value Of Carasent ASA (OB:CARA)

May 23

We Like These Underlying Trends At Carasent (OB:CARA)

Feb 28

What Type Of Shareholders Own The Most Number of Carasent ASA (OB:CARA) Shares?

Jan 24

Earnings and Revenue Growth Forecasts

OB:CARA - Analysts future estimates and past financials data (NOK Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2026	417	44	55	107	4
12/31/2025	365	20	38	87	4
12/31/2024	280	-17	-43	38	4
9/30/2024	265	-8	-25	25	N/A
6/30/2024	254	-10	-33	19	N/A
3/31/2024	251	-56	-61	-4	N/A
12/31/2023	244	-46	-74	-4	N/A
9/30/2023	235	-64	-86	-3	N/A
6/30/2023	227	-49	-83	10	N/A
3/31/2023	210	5	-71	27	N/A
12/31/2022	195	31	-58	34	N/A
9/30/2022	179	47	-40	37	N/A
6/30/2022	168	15	-29	36	N/A
3/31/2022	154	33	-3	47	N/A
12/31/2021	137	0	-6	32	N/A
9/30/2021	117	-33	-1	29	N/A
6/30/2021	98	-21	11	33	N/A
3/31/2021	83	-46	2	21	N/A
12/31/2020	71	-38	3	19	N/A
9/30/2020	64	-14	5	21	N/A
6/30/2020	58	-4	3	18	N/A
3/31/2020	52	3	1	15	N/A
12/31/2019	48	3	2	12	N/A
9/30/2019	44	2	2	11	N/A
6/30/2019	40	0	1	7	N/A
3/31/2019	35	-3	-3	2	N/A
12/31/2018	24	-7	-2	0	N/A
9/30/2018	14	12	30	31	N/A
6/30/2018	6	18	N/A	52	N/A
3/31/2018	N/A	19	N/A	52	N/A
12/31/2017	N/A	20	N/A	51	N/A
9/30/2017	25	128	N/A	-6	N/A
6/30/2017	79	131	N/A	-16	N/A
3/31/2017	136	139	N/A	-24	N/A
12/31/2016	194	142	N/A	-36	N/A
9/30/2016	205	3	N/A	-33	N/A
6/30/2016	234	56	N/A	-60	N/A
3/31/2016	259	56	N/A	-42	N/A
12/31/2015	305	61	N/A	-32	N/A
9/30/2015	322	-31	N/A	4	N/A
6/30/2015	307	-80	N/A	24	N/A
3/31/2015	314	-84	N/A	22	N/A
12/31/2014	294	-79	N/A	24	N/A
9/30/2014	255	2	N/A	25	N/A
6/30/2014	248	2	N/A	23	N/A
3/31/2014	246	3	N/A	23	N/A
12/31/2013	254	5	N/A	29	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: CARA is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.4%).

Earnings vs Market: CARA is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: CARA is expected to become profitable in the next 3 years.

Revenue vs Market: CARA's revenue (18.6% per year) is forecast to grow faster than the Norwegian market (2.2% per year).

High Growth Revenue: CARA's revenue (18.6% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: CARA's Return on Equity is forecast to be low in 3 years time (4.2%).

Carasent Future Growth

Future criteria checks 4/6

Key information

Recent future growth updates

Price target decreased by 9.4% to kr29.00

Consensus EPS estimates upgraded to kr0.53 loss

Price target decreased by 12% to kr33.50

Price target decreased by 8.6% to kr37.00

Consensus forecasts updated

Price target decreased to kr40.50

Recent updates

Carasent ASA (OB:CARA) acquired Data - Al GmbH.

Third quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

High number of new and inexperienced directors

Eg Norge A/S contemplates launching a voluntary cash offer to acquire Carasent ASA (OB:CARA) for NOK 1.4 billion.

Eg Norge A/S contemplates launching a voluntary cash offer to acquire Carasent ASA (OB:CARA) for NOK 1.4 billion.

First quarter 2024 earnings released: kr0.15 loss per share (vs kr0.01 loss in 1Q 2023)

Carasent ASA's (OB:CARA) 32% Jump Shows Its Popularity With Investors

New major risk - Share price stability

Carasent ASA Announces Changes to Its Board

Full year 2023 earnings: EPS exceeds analyst expectations

Chief Executive Officer recently bought kr1.4m worth of stock

Independent Director recently bought kr100k worth of stock

Full year 2023 earnings: EPS exceeds analyst expectations

Founder recently bought kr28m worth of stock

High number of new and inexperienced directors

Calculating The Fair Value Of Carasent ASA (OB:CARA)

Carasent ASA Announces Staffan Hanstorp Resigns as A Member of the Board of Directors

Carasent ASA to Report Fiscal Year 2023 Results on Mar 22, 2024

Chief Financial Officer recently bought kr165k worth of stock

Is It Too Late To Consider Buying Carasent ASA (OB:CARA)?

New minor risk - Share price stability

Carasent Asa Approves Dividend

Independent Director recently bought kr111k worth of stock

Upcoming dividend of kr1.84 per share

Price target decreased by 9.4% to kr29.00

Chief Executive Officer recently bought kr96k worth of stock

Carasent's (OB:CARA) Returns On Capital Are Heading Higher

Chief Executive Officer recently bought kr97k worth of stock

Second quarter 2023 earnings: EPS misses analyst expectations

Consensus EPS estimates upgraded to kr0.53 loss

Carasent ASA's (OB:CARA) Intrinsic Value Is Potentially 73% Above Its Share Price

Price target decreased by 12% to kr33.50

First quarter 2023 earnings released: kr0.01 loss per share (vs kr0.32 profit in 1Q 2022)

Is Carasent ASA (OB:CARA) Potentially Undervalued?

Full year 2022 earnings released: EPS: kr0.39 (vs kr0.002 loss in FY 2021)

Price target decreased by 8.6% to kr37.00

Carasent ASA to Report Q1, 2023 Results on May 04, 2023

Is Now The Time To Look At Buying Carasent ASA (OB:CARA)?

High number of new and inexperienced directors

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

Consensus forecasts updated

Price target decreased to kr40.50

Carasent ASA (OB:CARA) acquired HPI Health Profile Institute AB for SEK 35 million.

Carasent ASA Provides Earnings Guidance for the Third Quarter and Full Year 2022

Carasent Asa Announces That Johan Lindqvist to Step Down as Chairman of the Board

Price target decreased to kr44.50

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

Investor sentiment improved over the past week

Price target decreased to kr46.50

Investor sentiment improved over the past week

Consensus forecasts updated

Price target decreased to kr48.50

Carasent's (OB:CARA) Solid Profits Have Weak Fundamentals

First quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Returns Are Gaining Momentum At Carasent (OB:CARA)

Dennis Höjer Informs that He Will Step Down as CEO of Carasent ASA

No independent directors

Full year 2021 earnings: EPS misses analyst expectations

Carasent ASA Beat Analyst Profit Forecasts, And Analysts Have New Estimates

Full year 2021 earnings: EPS misses analyst expectations

Price target decreased to kr54.00

Carasent ASA (OB:CARA) completed the acquisition of Medrave Software AB.

Carasent ASA (OB:CARA) agreed to acquire Medrave Software AB for approximately SEK 130 million.

There Are Reasons To Feel Uneasy About Carasent's (OB:CARA) Returns On Capital

Price target increased to kr61.00

Third quarter 2021 earnings released: kr0.28 loss per share (vs kr0.21 loss in 3Q 2020)

Second quarter 2021 earnings released: EPS kr0.34 (vs kr0.14 loss in 2Q 2020)

Chief Financial Officer Lars Forsberg has left the company

Carasent ASA announced that it has received NOK 420.155987 million in funding from Cardigan Holdco S.à r.l.